Latest news with #TheCooperCompanies
Yahoo
3 days ago
- Business
- Yahoo
XRAY vs. COO: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Dentsply International (XRAY) or The Cooper Companies (COO). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits. Dentsply International and The Cooper Companies are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. This means that XRAY's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors. Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels. The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors. XRAY currently has a forward P/E ratio of 8.64, while COO has a forward P/E of 20.09. We also note that XRAY has a PEG ratio of 1.17. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. COO currently has a PEG ratio of 2.02. Another notable valuation metric for XRAY is its P/B ratio of 1.62. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, COO has a P/B of 1.96. These are just a few of the metrics contributing to XRAY's Value grade of A and COO's Value grade of C. XRAY has seen stronger estimate revision activity and sports more attractive valuation metrics than COO, so it seems like value investors will conclude that XRAY is the superior option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates
The Cooper Companies (COO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.23%. A quarter ago, it was expected that this surgical and contact lens products maker would post earnings of $0.92 per share when it actually produced earnings of $0.92, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates three times. The Cooper Companies , which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $1 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 0.67%. This compares to year-ago revenues of $942.6 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. The Cooper Companies shares have lost about 12.9% since the beginning of the year versus the S&P 500's gain of 0.1%. While The Cooper Companies has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for The Cooper Companies: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.05 on $1.07 billion in revenues for the coming quarter and $3.98 on $4.12 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the broader Zacks Medical sector, Plus Therapeutics (PSTV), is yet to report results for the quarter ended March 2025. This developer of cell therapies is expected to post quarterly loss of $0.17 per share in its upcoming report, which represents a year-over-year change of +77.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Plus Therapeutics' revenues are expected to be $1.85 million, up 10.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report Plus Therapeutics, Inc. (PSTV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
5 days ago
- Business
- Yahoo
The Cooper Companies (COO) Reports Q2 Earnings: What Key Metrics Have to Say
The Cooper Companies (COO) reported $1 billion in revenue for the quarter ended April 2025, representing a year-over-year increase of 6.3%. EPS of $0.96 for the same period compares to $0.85 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $995.61 million, representing a surprise of +0.67%. The company delivered an EPS surprise of +3.23%, with the consensus EPS estimate being $0.93. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how The Cooper Companies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue by Geography- Americas: $282.40 million versus the two-analyst average estimate of $288.77 million. The reported number represents a year-over-year change of +6.8%. Revenue by Geography- Asia Pacific: $138.60 million compared to the $136.60 million average estimate based on two analysts. The reported number represents a change of +3.1% year over year. Revenue by Geography- EMEA: $248.60 million versus the two-analyst average estimate of $243.81 million. The reported number represents a year-over-year change of +4.9%. Revenue by Category- CVI: $669.60 million versus $669.02 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +5.3% change. Revenue by Category- CSI: $332.70 million versus the six-analyst average estimate of $329.54 million. The reported number represents a year-over-year change of +8.5%. Revenue by Category- CSI- Office and surgical: $205.80 million versus $195.05 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +12.5% change. Revenue by Category- CSI- Fertility: $126.90 million compared to the $135.30 million average estimate based on five analysts. The reported number represents a change of +2.5% year over year. Revenue by Category- CVI- Sphere, other: $341.20 million versus $337.28 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change. Revenue by Category- CVI- Toric and multifocal: $328.40 million versus the five-analyst average estimate of $331.93 million. The reported number represents a year-over-year change of +5.8%. View all Key Company Metrics for The Cooper Companies here>>>Shares of The Cooper Companies have returned -1.9% over the past month versus the Zacks S&P 500 composite's +6.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
14-05-2025
- Business
- Yahoo
The Cooper Companies, Inc. (COO): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
We recently published a list of . In this article, we are going to take a look at where The Cooper Companies, Inc. (NASDAQ:COO) stands against other small-cap healthcare stocks hedge funds are buying. The U.S. healthcare sector has performed better in 2025 compared to the broader market. After two years of weak performance, the healthcare sector kicked off on a strong note in 2025. In a letter from Federated Hermes, within the S&P 500, the healthcare sector soared nearly 2.59% as of April 30. Whereas the Information Technology sector reported an 11.24% loss, the Consumer Discretionary sector was down 14.08%, and the S&P 500 recorded a 4.92% decline as a whole. READ ALSO: Why These 15 Healthcare Stocks Are Surging in 2025 As inflation eases, things will be better economically for the healthcare sector. The Investment Director of Federated Hermes, Jordan Stuart, mentioned that when inflation has eased historically, healthcare stocks have performed better. Stuart added: 'Typically, healthcare stocks underperform when inflation is high due to increased costs and pricing pressures. However, inflation has, ever so slowly, begun to decline again, and optimism around rate cuts has resurfaced, giving life back to healthcare stocks. This shift in economic conditions will likely enhance the attractiveness of health care investments, as lower inflation and interest rates create a more favourable environment for growth and profitability.' According to BlackRock, an average of 75% of healthcare companies exceeded earnings expectations in the first three quarters of 2024. This led to an improved local investor sentiment, with nearly $80 million of inflows to the iShares Global Healthcare ETF (IXJ) in 2024. BlackRock expects the 2025 projected earnings in the healthcare sector to rebound even further, recording the highest year-over-year growth in 18 years, excluding the COVID-19 period. The U.S. healthcare sector now accounts for a fifth of the U.S. economy. With digital transformation, non-acute care shifts, and innovation in biosimilars and speciality drugs, the healthcare sector remains poised for growth in 2025. According to SNS Insider Research, the healthcare market is expected to reach $44.76 trillion in 2032 from $21.22 trillion reported in 2023. This marks a CAGR of 9.07% between 2024 and 2032. North America accounts for almost 44% of the global healthcare market share. Trump's tariffs remain a major hurdle for healthcare, and they may threaten around a 10-15% cost increase for drugs and medical devices, as per Forbes. According to the Medical Device Network, around 69% of the U.S.-marketed medical devices are manufactured outside of the U.S. David Risinger from Leerink Partners highlighted that potential tariffs would likely drive the U.S. drug prices, even though the companies moved their production to the U.S. Reducing costs with domestic production could take years, added Risinger. Reportedly, President Trump is expected to sign an executive order to slash U.S. prescription drug prices. The President plans to match drug prices overseas and control the price hike anticipated by analysts. Lately, the U.S. government has been striving to make trade deals with its partners. After talks between the U.S. and China, both countries have decided to slash tariffs for 90 days, with duties set to drop by 115 percentage points. This move will drop American tariffs on Chinese goods to as low as 30%, and China's retaliatory duties will go down from 125% to 10%. To compile the list of the 15 small-cap healthcare stocks hedge funds are buying, we used the Finviz screener to shortlist healthcare stocks that are trading at a market cap of at least $10 billion. For this article, we are defining small-cap stocks as those that trade between $10 billion and $20 billion. We have ranked the stocks in ascending order of the number of hedge fund holders. Data for the number of hedge fund investors for each stock was taken from Insider Monkey's database, updated as of Q4 2024. In cases where two or more stocks were held by an equal number of hedge funds, we used the upside potential as a tiebreaker. The analysts' upside potential data is taken from CNN. Please note that the data was collected on May 13, 2025. Why are we interested in the stocks that hedge funds and billionaire investors pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A doctor wearing gloves and a mask holding a pair of contact lenses in their hand. No. of Hedge Fund Holders: 52 Market Capitalization: $16.49 Billion Analyst Upside: 29.67% Incorporated back in 1958, The Cooper Companies, Inc. (NASDAQ:COO) is a leading global medical device firm. The company operates through two units: CooperVision and CooperSurgical. CooperVision is engaged in the contact lens industry, while CooperSurgical deals with fertility and women's healthcare. The Cooper Companies, Inc. (NASDAQ:COO) is well on track to record another strong quarter. The company has surpassed earnings estimates in all four past quarters. However, the COO missed revenue in Q1 due to CooperSurgical's seasonality. During Q2, the company is expected to post earnings of $0.92 per share, up by 9.5% from a year ago, driven by CooperVision's daily lens growth and margin expansion. Analysts project the revenue to be around $995 million, up by almost 7.4% year-over-year. For the full year 2025, the company is anticipated to generate revenue between $4.08 billion and $4.16 billion, indicating 6-8% organic growth. On the Street, COO stock sports a consensus Strong Buy rating. The average price target of $108.56 implies an upside of 33% from current levels. Overall, COO ranks 9th on our list of small-cap healthcare stocks hedge funds are buying. While we acknowledge the potential of COO to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that has gone up since the beginning of 2025, while popular AI stocks have lost around 25%. If you are looking for an AI stock that is more promising than COO but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-04-2025
- Business
- Yahoo
Investors three-year losses continue as Cooper Companies (NASDAQ:COO) dips a further 13% this week, earnings continue to decline
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. Unfortunately, that's been the case for longer term The Cooper Companies, Inc. (NASDAQ:COO) shareholders, since the share price is down 28% in the last three years, falling well short of the market return of around 16%. And over the last year the share price fell 26%, so we doubt many shareholders are delighted. Shareholders have had an even rougher run lately, with the share price down 21% in the last 90 days. However, one could argue that the price has been influenced by the general market, which is down 15% in the same timeframe. Since Cooper Companies has shed US$2.2b from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. During the three years that the share price fell, Cooper Companies' earnings per share (EPS) dropped by 24% each year. This fall in the EPS is worse than the 10% compound annual share price fall. This suggests that the market retains some optimism around long term earnings stability, despite past EPS declines. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). We know that Cooper Companies has improved its bottom line lately, but is it going to grow revenue? You could check out this free report showing analyst revenue forecasts . While the broader market lost about 2.4% in the twelve months, Cooper Companies shareholders did even worse, losing 26%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 0.4% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling. We will like Cooper Companies better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
